GL1X · GenesisL1 explorer

MolNFT v1 · #91405 · protein

Potent and selective phosphodiesterase 10A inhibitors

4FCB · Camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase…: “Potent and selective phosphodiesterase 10A inhibitors”. X-ray diffraction, 3 ligands (0T7, ZN, MG), 8 pockets (best druggability 0.73). MolNFT v1 #91405 on GenesisL1: 3D…

PDB
4FCB
Type
protein
Length
632 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10A
EC
3.1.4.17, 3.1.4.35
UniProt
Q9Y233
Ligands
0T7, ZN, MG
Pockets
8 · best druggability 0.73

Structure

x-ray diffraction · 2 distinct chains · 71% helix, 0% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACamp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10A (EC 3.1.4.17, 3.1.4.35)protein32271% helix, 0% strandQ9Y233
BCamp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10A (EC 3.1.4.17, 3.1.4.35)protein31070% helix, 0% strandQ9Y233

Ligands and binding sites

  • 0T7 · 3,4-dimethyl-1-propyl-7-(quinolin-2-ylmethoxy)imidazo[1,5-a]quinoxaline · ligand · 2 copies · chains A, B
  • ZN · Zinc ion · metal · 2 copies · chains A, B
  • MG · Magnesium ion · metal · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

8 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16200.730.8069MG, 0T7
24280.710.8246MG, 0T7
36720.700.7849empty
4600.550.8817empty
5800.350.7614empty

Interfaces

1 interface between chains.

  • A–B · 823 Ų buried · 10 hydrogen bonds · protein-protein

Compared structures

  • 4FCB · Potent and Selective Phosphodiesterase 10A Inhibitors · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.